David H. Schwartz, Ph.D.
Head of Scientific Support to Counsel
A “scientific detective,” Dr. Schwartz excels at analyzing how science and law interact. As head of ISS’ Support to Counsel practice, he helps clients defend and support pharmaceuticals, industrial chemicals, medical devices, foods, and dietary supplements in the courts, the regulatory arena, and the market place. With a talent for communicating complex scientific information, Dr. Schwartz has become a go-to for lawyers, business professionals, and financial and investment firms. Dr. Schwartz specializes in providing strategic and tactical support to counsel in legal cases involving complex scientific issues. He has played a lead role in winning multi-billion dollar legal cases for clients. With the sheer weight of the scientific data he’s able to collect, evaluate, and present as evidence, he’s helped counsel win cases before going to trial, saving ISS clients time and money.
Dr. Schwartz counts Daubert hearings among his biggest successes. His expertise guides the ISS team across all disciplines related to the health sciences: toxicology, epidemiology, environmental health and safety, biostatistics, pharmacology, and regulatory affairs.
He has pioneered programs to critically review the scientific foundation of an adversary's case and provided persuasive, evidence-based responses. For 20 years, he has worked with the legal community evaluating product safety and defending a host of products and exposures, including the following: welding rods, cellular phones, ionizing and non-ionizing radiation, hydraulic fracturing and other drilling technologies, breast implants, wound care products, dietary supplements, general healthcare products, and a host of over-the-counter and prescription pharmaceutical agents (including: antidepressants, dermatologics, anti-malarials, anxiolytics, antipsychotics, and diet drugs).
Prior to founding ISS, Dr. Schwartz served as the Director of Scientific Litigation Support for the law firm McCarter and English, where he played a principal role in the safety evaluation of Prozac. Since then, he has guided clients using scientific principles to defend products before, during, and after launch.
Dr. Schwartz received a Ph.D. in Neuroscience from Princeton University and postdoctoral training in Neuropharmacology and Neurophysiology from the Center for Molecular and Behavioral Neuroscience at Rutgers University.